JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on DBV Technologies SA – American (DBVT – Research Report) today and set a price target of $10.00.
Jonathan Wolleben’s rating is based on the promising potential of Viaskin Peanut as a leading solution for peanut allergies in children. The treatment has garnered significant interest from allergists, particularly due to its safety and ease of use, which are critical factors for the target age group of 1-7 years. Unlike other treatments such as Xolair, which face challenges like needle phobia and high costs, Viaskin Peanut offers a non-invasive alternative that is gaining traction in the medical community.
Furthermore, recent long-term data has shown that Viaskin Peanut not only maintains but improves its effectiveness and safety over time. This positions it as a potential blockbuster in the market, addressing a significant unmet need for a widely accepted peanut allergy treatment. Despite the company’s current market valuation reflecting its need for additional capital, the path to success appears largely de-risked, with key trials designed for success. This combination of factors underpins Wolleben’s Buy rating for DBV Technologies.